{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:48:28Z","timestamp":1792097308966,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03375-7","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:59:19Z","timestamp":1789451959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fgl-1 promotes the progression of endometrial adenocarcinoma through PI3K\/AKT signal pathway"],"prefix":"10.1007","volume":"43","author":[{"given":"Wenjing","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyue","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"12","key":"3375_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.mpdhp.2021.09.003","volume":"27","author":"M Masood","year":"2021","unstructured":"Masood M, Singh N. Endometrial carcinoma: changes to classification (WHO 2020). Diagn Histopathol. 2021;27(12):493\u20139.","journal-title":"Diagn Histopathol"},{"issue":"10333","key":"3375_CR2","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","volume":"399","author":"EJ Crosbie","year":"2022","unstructured":"Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412\u201328.","journal-title":"Lancet"},{"key":"3375_CR3","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2024.1651","volume":"18","author":"OA Olatunde","year":"2024","unstructured":"Olatunde OA, Samaila MO, Imam MI, Uchime KE, Dauda SE. Histopathological patterns of endometrial carcinoma in a tertiary hospital in North-West Nigeria. ecancermedicalscience. 2024;18:1651.","journal-title":"ecancermedicalscience"},{"key":"3375_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.109821","volume":"124","author":"S Tan","year":"2020","unstructured":"Tan S, Li D, Zhu X. Cancer immunotherapy: pros, cons and beyond. Biomed Pharmacother. 2020;124:109821.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"3375_CR5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","volume":"20","author":"SP Kubli","year":"2021","unstructured":"Kubli SP, Berger T, Araujo DV, Siu LL, Mak TW. Beyond immune checkpoint blockade: emerging immunological strategies. Nat Rev Drug Discov. 2021;20(12):899\u2013919.","journal-title":"Nat Rev Drug Discov"},{"key":"3375_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1296341","volume":"14","author":"A Parvez","year":"2023","unstructured":"Parvez A, Choudhary F, Mudgal P, Khan R, Qureshi KA, Farooqi H, et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front Immunol. 2023;14:1296341.","journal-title":"Front Immunol"},{"issue":"3","key":"3375_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/07357907.2021.2012188","volume":"40","author":"Y Dai","year":"2022","unstructured":"Dai Y, Muaibati M, Xie W, Abasi A, Li K, Tong Q, et al. PD-1\/PD-L1 inhibitors monotherapy for the treatment of endometrial cancer: meta-analysis and systematic review. Cancer Investig. 2022;40(3):293\u2013309.","journal-title":"Cancer Investig"},{"issue":"16","key":"3375_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164032","volume":"15","author":"MN MamatYusof","year":"2023","unstructured":"MamatYusof MN, Chew KT, Hafizz AMHA, Abd Azman SH, Ab Razak WS, Hamizan MRu, et al. Efficacy and safety of PD-1\/PD-L1 inhibitor as single-agent immunotherapy in endometrial cancer: a systematic review and meta-analysis. Cancers (Basel). 2023;15(16):4032.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3375_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000651","volume":"8","author":"H Zeng","year":"2020","unstructured":"Zeng H, Zhou Q, Wang Z, Zhang H, Liu Z, Huang Q, et al. Stromal LAG-3+ cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture. J Immunother Cancer. 2020;8(1):e000651.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"3375_CR10","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.3390\/biomedicines10112826","volume":"10","author":"M Koz\u0142owski","year":"2022","unstructured":"Koz\u0142owski M, Borzyszkowska D, Cymbaluk-P\u0142oska A. The role of TIM-3 and LAG-3 in the microenvironment and immunotherapy of ovarian cancer. Biomedicines. 2022;10(11):2826.","journal-title":"Biomedicines"},{"issue":"3","key":"3375_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/14737140.2022.2039124","volume":"22","author":"J Tian","year":"2022","unstructured":"Tian J, Liu Y, Zhang T, Yue L, Xiao Y, Guo C. LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy. Expert Rev Anticancer Ther. 2022;22(3):289\u201396.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"3375_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003776","volume":"10","author":"P Sch\u00f6ffski","year":"2022","unstructured":"Sch\u00f6ffski P, Tan DS, Mart\u00edn M, Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, et al. Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525)\u00b1anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer. 2022;10(2):e003776.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"3375_CR13","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1007\/s11033-020-05435-1","volume":"47","author":"N Jiang","year":"2020","unstructured":"Jiang N, Dai Q, Su X, Fu J, Feng X, Peng J. Role of PI3K\/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 2020;47(6):4587\u2013629.","journal-title":"Mol Biol Rep"},{"key":"3375_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.819128","volume":"12","author":"Y Peng","year":"2022","unstructured":"Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway? Front Oncol. 2022;12:819128.","journal-title":"Front Oncol"},{"issue":"6","key":"3375_CR15","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s11010-022-04587-x","volume":"478","author":"K Ramasubbu","year":"2023","unstructured":"Ramasubbu K, Rajeswari VD. Impairment of insulin signaling pathway PI3K\/Akt\/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review. Mol Cell Biochem. 2023;478(6):1307\u201324.","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"3375_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000987","volume":"8","author":"HHM Ng","year":"2020","unstructured":"Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, et al. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1\/PD-L1 immunotherapy in hepatocellular carcinoma. J Immunother Cancer. 2020;8(2):e000987.","journal-title":"J Immunother Cancer"},{"key":"3375_CR17","doi-asserted-by":"publisher","unstructured":"Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature [Internet]. 2013;497:67\u201373. Available from: https:\/\/doi.org\/10.1038\/nature12113","DOI":"10.1038\/nature12113"},{"issue":"4","key":"3375_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195655","volume":"13","author":"T Haruma","year":"2018","unstructured":"Haruma T, Nagasaka T, Nakamura K, Haraga J, Nyuya A, Nishida T, et al. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability. PLoS ONE. 2018;13(4):e0195655.","journal-title":"PLoS ONE"},{"issue":"1","key":"3375_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG 3 (CD 223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80\u201396.","journal-title":"Immunol Rev"},{"key":"3375_CR20","doi-asserted-by":"crossref","unstructured":"Goldberg MV, Drake CG. LAG-3 in cancer immunotherapy. Cancer Immunol Immunother. 2010;269\u2013278.","DOI":"10.1007\/82_2010_114"},{"issue":"7","key":"3375_CR21","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.4049\/jimmunol.1100714","volume":"187","author":"M Bettini","year":"2011","unstructured":"Bettini M, Szymczak-Workman AL, Forbes K, Castellaw AH, Selby M, Pan X, et al. Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J Immunol. 2011;187(7):3493\u20138.","journal-title":"J Immunol"},{"issue":"4","key":"3375_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"S-R Woo","year":"2012","unstructured":"Woo S-R, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917\u201327.","journal-title":"Cancer Res"},{"issue":"19","key":"3375_CR23","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1158\/1078-0432.CCR-09-0068","volume":"15","author":"C Brignone","year":"2009","unstructured":"Brignone C, Escudier B, Grygar C, Marcu M, Triebel F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res. 2009;15(19):6225\u201331.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3375_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10120-020-01151-8","volume":"24","author":"K Mimura","year":"2021","unstructured":"Mimura K, Kua L-F, Xiao J-F, Asuncion BR, Nakayama Y, Syn N, et al. Combined inhibition of PD-1\/PD-L1, LAG-3, and TIM-3 axes augments antitumor immunity in gastric cancer\u2013T cell coculture models. Gastric Cancer. 2021;24(3):611\u201323.","journal-title":"Gastric Cancer"},{"issue":"11","key":"3375_CR25","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1158\/2326-6066.CIR-19-0146","volume":"7","author":"H Zelba","year":"2019","unstructured":"Zelba H, Bedke J, Hennenlotter J, Mostb\u00f6ck S, Zettl M, Zichner T, et al. PD-1 and LAG-3 dominate checkpoint receptor\u2013mediated T-cell inhibition in renal cell carcinoma. Cancer Immunol Res. 2019;7(11):1891\u20139.","journal-title":"Cancer Immunol Res"},{"key":"3375_CR26","unstructured":"MacFarlane L-A. Regulation of Fibroblast Growth Factor-2 by an Endogenous Cis-antisense RNA, Library and Archives Canada= Biblioth\u00e8que et Archives Canada, Ottawa. 2011."},{"key":"3375_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112672","volume":"14","author":"C Yang","year":"2023","unstructured":"Yang C, Qian Q, Zhao Y, Huang B, Chen R, Gong Q, et al. Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma. Front Immunol. 2023;14:1112672.","journal-title":"Front Immunol"},{"key":"3375_CR28","doi-asserted-by":"crossref","unstructured":"Qu S, Dilimulati D, Du L, Huang X, Cai M, Zhang Y, Zhou D, Zhu J, Su L, Zhang M. The changes of serum fibrinogen-like protein 1 levels associated with improved liver function and uric acid after laparoscopic sleeve gastrectomy. 2022.","DOI":"10.21203\/rs.3.rs-1311106\/v1"},{"issue":"8","key":"3375_CR29","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1007\/s00125-016-3991-7","volume":"59","author":"H-T Wu","year":"2016","unstructured":"Wu H-T, Ou H-Y, Hung H-C, Su Y-C, Lu F-H, Wu J-S, et al. A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes. Diabetologia. 2016;59(8):1732\u201342.","journal-title":"Diabetologia"},{"key":"3375_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.579228","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu S, Guo Y, Lu L, Lu J, Ke M, Xu T, et al. Fibrinogen-like protein 1 is a novel biomarker for predicting disease activity and prognosis of rheumatoid arthritis. Front Immunol. 2020;11:579228.","journal-title":"Front Immunol"},{"issue":"35","key":"3375_CR31","doi-asserted-by":"publisher","first-page":"5946","DOI":"10.3748\/wjg.v27.i35.5946","volume":"27","author":"X-L Sun","year":"2021","unstructured":"Sun X-L, Qiao L-C, Gong J, Wen K, Xu Z-Z, Yang B-L. Proteomics identifies a novel role of fibrinogen-like protein 1 in Crohn\u2019s disease. World J Gastroenterol. 2021;27(35):5946.","journal-title":"World J Gastroenterol"},{"key":"3375_CR32","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.s374011","author":"D Dilimulati","year":"2022","unstructured":"Dilimulati D, Du L, Huang X, Jayachandran M, Cai M, Zhang Y, et al. Serum fibrinogen-like protein 1 levels in obese patients before and after laparoscopic sleeve gastrectomy: a six-month longitudinal study. Diabetes Metab Syndr Obes. 2022. https:\/\/doi.org\/10.2147\/dmso.s374011.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"3375_CR33","first-page":"1465","volume":"18","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Qiao H-X, Zhou Y-T, Hong L, Chen J-H. Fibrinogen-like-protein 1 promotes the invasion and metastasis of gastric cancer and is associated with poor prognosis. Mol Med Rep. 2018;18(2):1465\u201372.","journal-title":"Mol Med Rep"},{"issue":"3","key":"3375_CR34","first-page":"697","volume":"55","author":"F Bie","year":"2019","unstructured":"Bie F, Wang G, Qu X, Wang Y, Huang C, Wang Y, et al. Loss of FGL1 induces epithelial-mesenchymal transition and angiogenesis in LKB1 mutant lung adenocarcinoma. Int J Oncol. 2019;55(3):697\u2013707.","journal-title":"Int J Oncol"},{"issue":"2","key":"3375_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.bbrc.2015.07.078","volume":"465","author":"H Nayeb-Hashemi","year":"2015","unstructured":"Nayeb-Hashemi H, Desai A, Demchev V, Bronson RT, Hornick JL, Cohen DE, et al. Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development. Biochem Biophys Res Commun. 2015;465(2):167\u201373.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03375-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03375-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03375-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:41:52Z","timestamp":1792096912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03375-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3375"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03375-7","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of human tissues was approved by the Institutional Research Ethics Committees of Shandong Provincial Hospital, Affiliated with Shandong First Medical University (NSFC: NO. 2020\u2013906). Written informed consent was obtained from all participants before being included in the study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"289"}}